Edgewise Therapeutics initiated with Not Rated at Goldman Sachs

Goldman Sachs imitated coverage of Edgewise Therapeutics with a Not Rated. The firm sees promise in the company’s approach to targeting myosin in rare/orphan muscle diseases, initially with sevasemten in Becker muscular dystrophy followed by potential expansion into a post-gene therapy Duchenne muscular dystrophy population, and scalability into other areas including heart disease. Goldman does not assign a rating or price target to a biotechnology company until it has a drug, treatment, or medical device that has passed a Phase 2 clinical trial, or a license to distribute a post-Phase 2 drug, treatment, or medical device.